Forgot Password?
Return to Course Listing

CME: Inflammatory Bowel Disease (IBD): A Global Approach to Quality Management and Barriers to Care in an Era of Resource Consciousness

ACCREDITATION EXPIRED: January 30, 2018

Activity Description / Statement of Need:

In this online CME self-learning program:

 

Inflammatory bowel disease (IBD) is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are Crohn’s disease and ulcerative colitis (UC). Crohn’s disease affects any area of the alimentary canal, whereas ulcerative colitis is limited to the rectum and colon. Guidelines exist for the treatment of IBD, but they are constantly changing to include updated information. The World Gastroenterology Organization, for example, published updated practice guidelines in 2010 for IBD including extensive diagnosis and treatment criteria. The American College of Gastroenterology published updated practice guidelines in 2010 for ulcerative colitis and in 2009 for Crohn’s disease. The National Institute for Health and Clinical Excellence (NICE) released treatment guidelines for Crohn’s disease in 2013.Finally, NICE has provided much more recent clinical guidance and quality standards in 2015. Research suggests that healthcare professionals are oftentimes unable to keep up with the steady publishing of literature and evolution of clinical practice, continuing education learning activities in this area are warranted.

 

Agenda:

 

Introduction, Disclosures

Epidemiology of and risk factors for IBD

  • Statistics by type and severity
  • Causes and risk factors

Diagnostic pearls

  • Clinical features: endoscopic, radiologic, and histopathologic
  • Updates in imaging studies and technology [Learning Objective #1]
  • Patient case(s) [Learning Objectives #1]

Updates in the pharmacotherapy of IBD

  • Medications: induction and maintenance therapy for IBD [Learning Objective #2]
  • Novel and emerging therapies for the treatment of IBD
  • Patient case(s) [Learning Objectives #2 & 3]

Barriers to optimal care in patients with IBD [Learning Objective #5]

  • Managed care-related factors, including the prior authorization process
  • Adherence to therapy
  • Clinical factors, including relapses
  • Demographic barriers to care
  • Patient case(s)

Summary, conclusions, and best practice recap

Target Audience:

Healthcare professionals specializing in: gastroenterology, primary care, and those who otherwise commonly care for or clinically encounter patients with IBD.

This program is supported by an educational grant from SHIRE and VALEANT

Release Date: January 30, 2016 -- Expiration Date: January 30, 2018

Faculty: Raymond Cross, M.D., M.S., AGAF

Agenda

Learning Objectives

By the end of the session the participant will be able to:

  • Describe updates in the diagnosis of IBD.
  • Identify the present treatment options currently available for management of IBD and apply them to patient cases using evidence-based medicine.
  • Evaluate a treatment plan for a specific patient based on severity of IBD to optimize safety, efficacy, and cost-efficacy, suggesting modifications for improvement.
  • Identify new and emerging therapies for the treatment of IBD
  • Identify barriers to optimal care of patients with IBD and strategies to address them

Accreditation

ACCREDITATION HAS EXPIRED. NO CERTIFICATES WILL BE ISSUED.


Faculty Disclosure and Resolution of COI

 As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

 

Faculty Disclosure:  Raymond Cross, MD has received grant funding and/or is a consultant for Abbvie, Janssen, Shire, Takeda, and UCB.

 

Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.

 

Commercial Support Disclosure: This program is supported by an educational grant from SHIRE and VALEANT

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 50% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.